Cargando…
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
BACKGROUND: Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge. Previous rescue therapy for the treatment of chronic LAM-resistant hepatitis B infected patients included switching to entecavi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173393/ https://www.ncbi.nlm.nih.gov/pubmed/21824397 http://dx.doi.org/10.1186/1743-422X-8-393 |
_version_ | 1782211957077573632 |
---|---|
author | Sheng, Yun-Jian Liu, Jun-Ying Tong, Shi-Wen Hu, Huai-Dong Zhang, Da-Zhi Hu, Peng Ren, Hong |
author_facet | Sheng, Yun-Jian Liu, Jun-Ying Tong, Shi-Wen Hu, Huai-Dong Zhang, Da-Zhi Hu, Peng Ren, Hong |
author_sort | Sheng, Yun-Jian |
collection | PubMed |
description | BACKGROUND: Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge. Previous rescue therapy for the treatment of chronic LAM-resistant hepatitis B infected patients included switching to entecavir (ETV) and adding adefovir (ADV) or tenofovir (TFV). At present, switching to ETV is not recommended for rescue therapy for LAM-resistant chronic hepatitis B (CHB). The aim of this report was to determine whether add-on ADV was a superior rescue strategy in the treatment of CHB patients with LAM resistance. METHODS: We searched Medline/PubMed, EMBASE, Web of Knowledge, and the Cochrane Library. Relative risks (RRs) of virologic response, virologic breakthrough, normalization of serum alanine aminotransferase (ALT) levels and HBeAg seroconversion rates were studied. Factors predicting virologic response, standardized mean differences (SMD) in HBV DNA levels and safety were reviewed. RESULTS: Six eligible trials (451 patients in total) were included in the analysis. The rate of virologic breakthrough in the ETV group was higher than that in the LAM plus ADV group. There were no statistical differences in virologic response, ALT normalization and HBeAg seroconversion in either group 48 weeks post treatment. LAM plus ADV combination therapy produced faster and greater HBV DNA reduction rates 24 weeks post therapy compared to ETV monotherapy. HBV DNA baseline levels and the initial virologic response (IVR) were predictive of the virologic response. Additionally, combination therapy or monotherapy were both well tolerated. CONCLUSIONS: LAM plus ADV combination therapy was more effective and produced longer-lasting effects than switching to ETV monotherapy in treating CHB patients with LAM resistance. However, considering the practical benefits and limitations of ADV, individualized therapy will be needed in patients with prior history of LAM resistant infections. |
format | Online Article Text |
id | pubmed-3173393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31733932011-09-15 Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis Sheng, Yun-Jian Liu, Jun-Ying Tong, Shi-Wen Hu, Huai-Dong Zhang, Da-Zhi Hu, Peng Ren, Hong Virol J Review BACKGROUND: Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge. Previous rescue therapy for the treatment of chronic LAM-resistant hepatitis B infected patients included switching to entecavir (ETV) and adding adefovir (ADV) or tenofovir (TFV). At present, switching to ETV is not recommended for rescue therapy for LAM-resistant chronic hepatitis B (CHB). The aim of this report was to determine whether add-on ADV was a superior rescue strategy in the treatment of CHB patients with LAM resistance. METHODS: We searched Medline/PubMed, EMBASE, Web of Knowledge, and the Cochrane Library. Relative risks (RRs) of virologic response, virologic breakthrough, normalization of serum alanine aminotransferase (ALT) levels and HBeAg seroconversion rates were studied. Factors predicting virologic response, standardized mean differences (SMD) in HBV DNA levels and safety were reviewed. RESULTS: Six eligible trials (451 patients in total) were included in the analysis. The rate of virologic breakthrough in the ETV group was higher than that in the LAM plus ADV group. There were no statistical differences in virologic response, ALT normalization and HBeAg seroconversion in either group 48 weeks post treatment. LAM plus ADV combination therapy produced faster and greater HBV DNA reduction rates 24 weeks post therapy compared to ETV monotherapy. HBV DNA baseline levels and the initial virologic response (IVR) were predictive of the virologic response. Additionally, combination therapy or monotherapy were both well tolerated. CONCLUSIONS: LAM plus ADV combination therapy was more effective and produced longer-lasting effects than switching to ETV monotherapy in treating CHB patients with LAM resistance. However, considering the practical benefits and limitations of ADV, individualized therapy will be needed in patients with prior history of LAM resistant infections. BioMed Central 2011-08-08 /pmc/articles/PMC3173393/ /pubmed/21824397 http://dx.doi.org/10.1186/1743-422X-8-393 Text en Copyright ©2011 Sheng et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Sheng, Yun-Jian Liu, Jun-Ying Tong, Shi-Wen Hu, Huai-Dong Zhang, Da-Zhi Hu, Peng Ren, Hong Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis |
title | Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis |
title_full | Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis |
title_fullStr | Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis |
title_full_unstemmed | Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis |
title_short | Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis |
title_sort | lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis b: a systematic review and meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173393/ https://www.ncbi.nlm.nih.gov/pubmed/21824397 http://dx.doi.org/10.1186/1743-422X-8-393 |
work_keys_str_mv | AT shengyunjian lamivudineplusadefovircombinationtherapyversusentecavirmonotherapyforlamivudineresistantchronichepatitisbasystematicreviewandmetaanalysis AT liujunying lamivudineplusadefovircombinationtherapyversusentecavirmonotherapyforlamivudineresistantchronichepatitisbasystematicreviewandmetaanalysis AT tongshiwen lamivudineplusadefovircombinationtherapyversusentecavirmonotherapyforlamivudineresistantchronichepatitisbasystematicreviewandmetaanalysis AT huhuaidong lamivudineplusadefovircombinationtherapyversusentecavirmonotherapyforlamivudineresistantchronichepatitisbasystematicreviewandmetaanalysis AT zhangdazhi lamivudineplusadefovircombinationtherapyversusentecavirmonotherapyforlamivudineresistantchronichepatitisbasystematicreviewandmetaanalysis AT hupeng lamivudineplusadefovircombinationtherapyversusentecavirmonotherapyforlamivudineresistantchronichepatitisbasystematicreviewandmetaanalysis AT renhong lamivudineplusadefovircombinationtherapyversusentecavirmonotherapyforlamivudineresistantchronichepatitisbasystematicreviewandmetaanalysis |